GPR Variation in Nasopharynx Cases: Gamma Passing Rates for EPID-Based Quality Assurance

GPR variation in nasopharynx cases contains data from a study comparing two patient-specific quality assurance methods for radiation therapy. The dataset, shared by Shinhaeng Cho on figshare under a CC-BY-4.0 license, includes gamma passing rate results for prostate, nasopharynx, and breast cancer cases. It was last updated on May 14, 2026.

Use Cases

• Compare the sensitivity of EPID-based and Delta4 Phantom+ quality assurance methods based on gamma passing rate data.
• Analyze the impact of treatment isocenter displacement on gamma passing rates based on the described experimental results.
• Evaluate the clinical robustness of EPID-based PFF-PSQA based on the reported tolerance and action limits.
• Refine evaluation criteria for patient-specific quality assurance based on the comparison of passing rate thresholds.

Strengths

• Includes specific tolerance (99.5%) and action (99.4%) limits derived from the analysis.
• Compares results across three distinct cancer case types: prostate, nasopharynx, and breast.
• Dataset is openly licensed under CC-BY-4.0 for reuse.

Limitations

• Dataset size is only 33.8 KB, indicating a very limited scope.
• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.

Provenance

Source

Shinhaeng Cho

Collection Method

Data likely originates from a research study comparing EPID-based and Delta4 Phantom+ quality assurance methods on a Halcyon linear accelerator.

Freshness

Last updated 2026-05-14 17:41:58; freshness should be verified.